Aastrom's bone repair product shows promise in trial profiles
This article was originally published in Clinica
A feasibility clinical trial assessing Aastrom Biosciences' Tissue Repair Cells (TRCs) as a treatment for severe long bone non-union fractures has produced positive results, the Ann Arbor, Michigan firm has reported.
You may also be interested in...
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.